

Leqembi (lecanemab-irmb)

REFERRAL STATUS: New Referral Dose or Frequency Change Order Renewal

Infusion Office Preference: _____

PATIENT INFORMATION

Date:	Patient Name:	DOB:
<input type="checkbox"/> NKDA Allergies:	Weight (lbs / kg):	Height:
Patient Status: <input type="checkbox"/> New to Therapy <input type="checkbox"/> Continuing Therapy - Last Treatment Date:	Next Due Date:	

DIAGNOSIS AND ICD 10 CODE

<input type="checkbox"/> Alzheimer's disease with early onset	ICD 10 Code: G30.0
<input type="checkbox"/> Mild Cognitive Impairment, So stated	ICD 10 Code: G31.84
<input type="checkbox"/> other ICD10 Code:)	Description:

G30.X CODES BELOW REQUIRE SECONDARY F02.8x DIAGNOSIS CODE- PLEASE SELECT ONE FROM EACH COLUMN

		<u>Secondary</u>
<input type="checkbox"/> G30.1 Alzheimer's disease late onset	<input type="checkbox"/> F02.80 Dementia without behavioral disturbance	
<input type="checkbox"/> G30.8 Other Alzheimer's disease	<input type="checkbox"/> F02.81 Dementia with behavioral disturbance	
<input type="checkbox"/> G30.9 Alzheimer's disease , unspecified		

REQUIRED DOCUMENTATION

This signed order form by the provider Patient demographics AND insurance info Clinical/Progress notes

Prescriber must indicate that the following requirements have been met (provide supporting documentation)

Beta Amyloid Pathology Confirmed via:

↳ Amyloid PET Scan **OR** CFS Analysis-Date: _____ Result: _____

Cognitive Assessment Used: _____ Date: _____ Result: _____

ApoE εε4 Genetic Test - Date: _____ Result: Homozygote Heterozygote Noncarrier

MEDICARE REGISTRATION # IF APPLICABLE _____

MEDICATION ORDERS(Note: Only one stage of treatment may be ordered at a time)

<input type="checkbox"/> Stage 1 (Infusions #1-4) ✓ Leqembi 10mg/kg IV every two weeks x 4 doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> MRI of brain within one year prior to first infusion. Date of MRI: o By checking this box, I confirm that Beta Amyloid Pathology has been confirmed via CSF or PET.	<input type="checkbox"/> Stage 2 (Infusions #5 and #6) ✓ Leqembi 10mg/kg IV every two weeks x 2 doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #5. I have reviewed the results and clear patient to proceed with infusions #5 and #6.	<input type="checkbox"/> Stage 3 (Infusions #7-13) ✓ Leqembi 10mg/kg IV every two weeks x 7 doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #7. I have reviewed the results and clear patient to proceed with infusions #7 through #13.	* Stage 4 (Infusions #14 & beyond) <input type="checkbox"/> Leqembi 10mg/kg IV every two weeks over one hour. OR <input type="checkbox"/> Leqembi 10mg/kg IV every four weeks over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #14. I have reviewed the results and clear patient to proceed
--	---	---	---

Fax referral to 866-507-1164 or email to bionurses@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become 01/29/25part of the patient's medical record.

PRE-INFUSION :

- Confirm baseline MRI results prior to initiation of treatment
- Confirm MRI completed and reviewed by prescriber prior to the 5th, 7th, and 14th treatment
- Measure and record weight prior to each treatment to determine dose
- Hold infusion and notify provider if patient reports:
 - Headache
 - Dizziness
 - Nausea
 - Vision Changes
 - New or worsening confusion

Post -INFUSION :

- Educate patient/care partner to report headache, dizziness, nausea, vision changes, or new/worsening confusion.
- Fax infusion record to provider below :

PRESCRIBER INFORMATION

Provider Name (print)

Provider Signature**:

Date:

Office Phone

Office Fax

***Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI. Referring physician to monitor patient*

Fax referral to 866-507-1164 or email to bionurses@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become 01/29/25part of the patient's medical record.

Created 01/29/25